Adia Med Surges Ahead of Growth Timeline With Venture Medical Partnership in $25B Wound Care Market
Adia Nutrition Inc. (OTCQB: ADIA) has announced a strategic partnership between its clinical division, Adia Med, and Venture Medical to enter the $25 billion U.S. wound care market. The collaboration provides Adia Med with HCPCS billable products optimized for insurance reimbursement, targeting conditions like diabetic ulcers, venous ulcers, and pressure sores.
The partnership builds on Adia Med's existing approvals with UnitedHealthcare and Aetna, with active filings for TRICARE. Venture Medical will provide patient review and preliminary insurance verification services to streamline the reimbursement process. This expansion aligns with Adia Med's strategy to create a high-margin revenue stream while expanding access to advanced wound care solutions.
Adia Nutrition Inc. (OTCQB: ADIA) ha annunciato una partnership strategica tra la sua divisione clinica, Adia Med, e Venture Medical per entrare nel mercato statunitense della cura delle ferite da 25 miliardi di dollari. La collaborazione mette a disposizione di Adia Med prodotti fatturabili tramite HCPCS ottimizzati per il rimborso assicurativo, rivolti a patologie quali ulcere diabetiche, ulcere venose e piaghe da decubito.
La partnership si basa sulle approvazioni già ottenute da Adia Med con UnitedHealthcare e Aetna, con pratiche in corso per TRICARE. Venture Medical fornirà servizi di valutazione del paziente e verifica preliminare dell’assicurazione per snellire il processo di rimborso. Questa espansione è in linea con la strategia di Adia Med di creare una fonte di ricavi ad alto margine ampliando l’accesso a soluzioni avanzate per la cura delle ferite.
Adia Nutrition Inc. (OTCQB: ADIA) ha anunciado una alianza estratégica entre su división clínica, Adia Med, y Venture Medical para entrar en el mercado estadounidense de cuidado de heridas de 25 mil millones de dólares. La colaboración proporciona a Adia Med productos facturables bajo HCPCS optimizados para el reembolso por seguros, dirigidos a afecciones como úlceras diabéticas, úlceras venosas y úlceras por presión.
La asociación se apoya en las aprobaciones que Adia Med ya tiene con UnitedHealthcare y Aetna, y hay presentaciones activas para TRICARE. Venture Medical ofrecerá servicios de revisión del paciente y verificación preliminar del seguro para agilizar el proceso de reembolso. Esta expansión coincide con la estrategia de Adia Med de crear una fuente de ingresos de alto margen mientras amplía el acceso a soluciones avanzadas para el cuidado de heridas.
Adia Nutrition Inc. (OTCQB: ADIA)는 임상 부문인 Adia Med와 Venture Medical 간의 전략적 파트너십을 발표하며 미국 250억 달러 규모의 상처 치료 시장에 진출합니다. 이번 협력으로 Adia Med는 보험 환급에 적합하도록 최적화된 HCPCS 청구 가능 제품을 확보하게 되며, 당뇨성 궤양, 정맥성 궤양, 욕창 등 질환을 대상으로 합니다.
이 파트너십은 Adia Med가 이미 확보한 UnitedHealthcare 및 Aetna 승인 위에 구축되며 TRICARE에 대한 제출도 진행 중입니다. Venture Medical은 환자 검토 및 보험 사전 확인 서비스를 제공하여 환급 절차를 간소화할 예정입니다. 이번 확장은 고마진 수익원을 창출하고 첨단 상처 치료 솔루션에 대한 접근을 확대하려는 Adia Med의 전략과 일치합니다.
Adia Nutrition Inc. (OTCQB: ADIA) a annoncé un partenariat stratégique entre sa division clinique, Adia Med, et Venture Medical pour pénétrer le marché américain des soins des plaies de 25 milliards de dollars. La collaboration fournit à Adia Med des produits facturables HCPCS, optimisés pour le remboursement par les assurances, ciblant des affections telles que les ulcères diabétiques, les ulcères veineux et les escarres.
Le partenariat s’appuie sur les approbations déjà obtenues par Adia Med auprès de UnitedHealthcare et Aetna, avec des dossiers en cours pour TRICARE. Venture Medical fournira des services d’évaluation des patients et de vérification préliminaire des assurances afin de simplifier le processus de remboursement. Cette expansion s’aligne sur la stratégie d’Adia Med visant à créer une source de revenus à forte marge tout en élargissant l’accès à des solutions avancées de soins des plaies.
Adia Nutrition Inc. (OTCQB: ADIA) hat eine strategische Partnerschaft zwischen seiner klinischen Sparte Adia Med und Venture Medical angekündigt, um in den 25-Milliarden-Dollar-Wundversorgungsmarkt der USA einzutreten. Die Zusammenarbeit stellt Adia Med HCPCS-abrechenbare Produkte zur Verfügung, die für Versicherungsrückerstattungen optimiert sind und sich auf Erkrankungen wie diabetische Geschwüre, venöse Geschwüre und Druckgeschwüre konzentrieren.
Die Partnerschaft baut auf den bereits bestehenden Genehmigungen von Adia Med bei UnitedHealthcare und Aetna auf; für TRICARE laufen aktive Anträge. Venture Medical wird Patientenprüfungen und vorläufige Versicherungsverifizierungen anbieten, um den Erstattungsprozess zu vereinfachen. Diese Expansion entspricht Adia Meds Strategie, einen margenstarken Umsatzstrom zu schaffen und gleichzeitig den Zugang zu fortschrittlichen Wundbehandlungs-Lösungen zu erweitern.
- Entry into the large $25 billion U.S. wound care market
- Established insurance partnerships with major providers UnitedHealthcare and Aetna
- Access to insurance-ready HCPCS billable products through Venture Medical
- Streamlined insurance verification and reimbursement process
- Operating in highly competitive wound care market
- Success dependent on insurance approvals and reimbursement rates
Winter Park, Florida--(Newsfile Corp. - August 26, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a bold leader in regenerative medicine and personalized healthcare, today announced a thrilling partnership between its clinical division, Adia Med, and Venture Medical. This electrifying collaboration launches Adia Med into the epicenter of insurance-ready wound repair, igniting a high-margin revenue stream within the colossal
Venture Medical Logo
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/263748_venturemedicallogo_pr.jpg
Building on the momentum of its current nationwide commercial campaign for Adia Med, this strategic alliance with Venture Medical positions the company to capture a significant share of the rapidly growing wound care sector while making innovative care more accessible to patients in need. From diabetic ulcers to venous ulcers, pressure sores, and chronic skin injuries, Adia Med is equipped to address a wide range of conditions with cutting-edge solutions.
Through the partnership, Venture Medical provides Adia Med with a robust portfolio of HCPCS billable products, optimized for insurance reimbursement and tailored to individual patient conditions. Their expert support in patient review and preliminary insurance verification ensures treatments align seamlessly with payer requirements, streamlining reimbursement with precision and speed.
"This partnership is a major step forward for Adia Med," said Larry Powalisz, CEO of Adia Nutrition Inc. "Venture Medical's expertise and product supply enable us to scale rapidly into a high-demand, insurance-backed market that serves millions of Americans annually. We're not only creating a powerful new revenue stream but also delivering transformative wound care solutions to patients who need them most."
This exciting expansion strengthens Adia Med's payer integration strategy, building on existing approvals with UnitedHealthcare and Aetna, alongside active filings with TRICARE. By combining these payer relationships with Venture Medical's insurance-ready wound repair products and verification support, Adia Med is poised to gain significant ground in a large, stable, and growing market.
With this forward-thinking partnership, Adia Med is advancing its mission to drive meaningful patient impact while creating lasting, high-value opportunities for shareholders. The company is ready to make a bold mark on the future of wound care.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263748
FAQ
What is the partnership between Adia Med and Venture Medical?
What is the size of the wound care market that ADIA is entering?
Which insurance providers has ADIA secured approvals with?
What types of conditions will ADIA treat through this partnership?
How will the Venture Medical partnership benefit ADIA shareholders?
